Mirum Pharmaceuticals (NASDAQ:MIRM) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research report sent to investors on Friday, Benzinga reports. They currently have a $66.00 price target on the stock.

A number of other brokerages have also recently issued reports on MIRM. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $34.00 to $39.00 and gave the stock an outperform rating in a report on Monday, June 17th. Stifel Nicolaus reiterated a buy rating and issued a $48.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, June 17th. Citigroup upped their target price on Mirum Pharmaceuticals from $38.00 to $64.00 and gave the company a buy rating in a research report on Tuesday, June 18th. SVB Leerink cut their target price on Mirum Pharmaceuticals from $44.00 to $43.00 and set an outperform rating on the stock in a research report on Monday, March 18th. Finally, Baird R W upgraded Mirum Pharmaceuticals to a strong-buy rating in a report on Monday, June 17th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $53.64.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM opened at $34.19 on Friday. The stock has a 50 day moving average of $26.62 and a 200-day moving average of $27.22. The company has a market capitalization of $1.61 billion, a P/E ratio of -9.22 and a beta of 1.10. Mirum Pharmaceuticals has a 12 month low of $23.14 and a 12 month high of $35.56. The company has a current ratio of 3.68, a quick ratio of 3.47 and a debt-to-equity ratio of 1.31.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.14). The company had revenue of $69.22 million during the quarter, compared to analyst estimates of $69.71 million. Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. As a group, equities research analysts predict that Mirum Pharmaceuticals will post -1.66 EPS for the current year.

Insider Buying and Selling

In other news, Director Saira Ramasastry sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $25.68, for a total transaction of $128,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Pamela Vig sold 30,559 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $34.00, for a total value of $1,039,006.00. Following the completion of the transaction, the insider now owns 27,406 shares of the company’s stock, valued at $931,804. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Saira Ramasastry sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $25.68, for a total transaction of $128,400.00. The disclosure for this sale can be found here. 22.87% of the stock is owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of large investors have recently made changes to their positions in MIRM. AJOVista LLC acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth about $40,000. Wetzel Investment Advisors Inc. purchased a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at approximately $41,000. StepStone Group LP purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $135,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Mirum Pharmaceuticals by 447.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,394 shares of the company’s stock worth $159,000 after purchasing an additional 4,408 shares during the period. Finally, Quest Partners LLC purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $194,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.